LONGEVA.

IGF-1 LR3: adverse events and evidence limits

The listing names IGF-1 LR3, or Long R3 IGF-1, as lyophilized powder [1]. In the inspected primary abstract, Long [Arg3]-IGF-I has a 13-residue N-terminal extension and Glu-3 replaced by Arg. This defined analogue must remain distinct from native IGF-I and mecasermin [2].

The 1992 abstract describes DNA synthesis and other cell-culture responses, with relative activity varying across models [2]. Another inspected abstract describes LR3IGF-I in growing female rats: 14-day infusion through subcutaneously implanted osmotic pumps, assessing growth and metabolism [3]. These are experimental conditions, not a regimen for people.

Rat growth and cultured-cell DNA synthesis are not established clinical adverse reactions. These inspected abstracts do not provide human LR3 reaction frequencies or establish clinical product safety. They also cannot establish a causal human cancer risk or transfer another IGF-I preparation’s reaction list to LR3 [2][3].

What the studies reported

EffectModel or participantsHow often or as describedSource
Clinical adverse reactions in humansCell cultures [2]; growing female rats — 14-day infusion through subcutaneously implanted osmotic pumps [3]The inspected abstracts provide no human LR3 reaction frequencies; rat growth and cultured-cell DNA synthesis are not established clinical adverse reactions[2][3]

References

  1. Longeva (2026). IGF-1 LR3 https://longeva.bio/en/product/igf-1-lr3.
  2. Francis GL et al. (1992). Novel recombinant fusion protein analogues of insulin-like growth factor (IGF)-I indicate the relative importance of IGF-binding protein and receptor binding for enhanced biological potency. https://pubmed.ncbi.nlm.nih.gov/1378742/ doi:10.1677/jme.0.0080213.
  3. Tomas FM et al. (1993). Anabolic effects of insulin-like growth factor-I (IGF-I) and an IGF-I variant in normal female rats. https://pubmed.ncbi.nlm.nih.gov/8371075/ doi:10.1677/joe.0.1370413.